Intravenous minocycline in acute stroke: A randomized, controlled pilot study and meta-analysis

Stroke

Volumn 44, Issue 9, 2013, Pages 2493-2499

  Kohler, Edith ^a   Prentice, David A ^a   Bates, Timothy R ^b   Hankey, Graeme J ^a   Claxton, Anne ^a   Van Heerden, Jolandi ^c   Blacker, David ^c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b Swan District Hospital   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Hemorrhagic stroke; Ischemic stroke; Minocycline; Neuroprotection; Stroke

Indexed keywords

MINOCYCLINE;

AGED; ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HANDICAP FREE SURVIVAL; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SINGLE BLIND PROCEDURE; TIME TO TREATMENT; URINARY TRACT INFECTION;

HEMORRHAGIC STROKE; ISCHEMIC STROKE; MINOCYCLINE; NEUROPROTECTION; STROKE;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME;

EID: 84884502741     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.000780     Document Type: Article

References (24)

1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6:182-187.
2. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol. 2004;3:744-751.
3. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA. 1999;96:13496-13500.
4. Wang CX, Yang T, Noor R, Shuaib A. Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol. 2002;2:2.
5. Morimoto N, Shimazawa M, Yamashima T, Nagai H, Hara H. Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res. 2005;1044:8-15.
6. Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004;4:7.
7. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci. 2004;24:2182-2190.
8. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA. 2004;101:3071-3076.
9. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001;48:1393-1401.
10. Power C, Henry S, Del Bigio MR, Larsen PH, Corbett D, Imai Y, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol. 2003;53:731-742.
11. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol. 2010;67:1442-1448.
12. Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain. 2003;126(Pt 7):1628-1637.
13. Matsukawa N, Yasuhara T, Hara K, Xu L, Maki M, Yu G, et al. Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci. 2009;10:126.
14. Machado LS, Sazonova IY, Kozak A, Wiley DC, El-Remessy AB, Ergul A, et al. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke. 2009;40:3028-3033.
15. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31:3034-3040.
16. Lee CZ, Xue Z, Zhu Y, Yang GY, Young WL. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Stroke. 2007;38:2563-2568.
17. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008;39:3372-3377.
18. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology. 2007;69:1404-1410.
19. Padma Srivastava MV, Bhasin A, Bhatia R, Garg A, Gaikwad S, Prasad K, et al. Efficacy of minocycline in acute ischemic stroke: a singleblinded, placebo-controlled trial. Neurol India. 2012;60:23-28.
20. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
21. Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke. 2010;41:2283-2287.
22. Janssen PM, Visser NA, Dorhout Mees SM, Klijn CJ, Algra A, Rinkel GJ. Comparison of telephone and face-to-face assessment of the modified Rankin Scale. Cerebrovasc Dis. 2010;29:137-139.
23. Blacker DJ, Prentice D, Hankey GJ, Bynevelt M, Kohler E, Bates TR, et al. The West Australian Intravenous Minocycline and tPA Stroke Study (WAIMATSS). Int J Stroke. 2012;7:13.
24. Hess DC, Howard VJ, Howard G. Minocycline: the search for a community hospital acute stroke therapy. Neurol India. 2012;60:1-2.